Cardio-Renal-Metabolic (CVRM) Innovation Pharma Partnering Summit

The Cardio-Renal-Metabolic (CVRM) Innovation Pharma Partnering Summit is a hyper-aligned business development forum for companies addressing pathologies driving cardiovascular, kidney, and metabolic diseases.

This exclusive summit brings together over 80 on-scope and in-strategy companies, providing targeted face-to-face networking, and opportunities to validate biotech innovations against the interests of pharma and qualified investors.

Designed to maximize your success, the scientifically focused environment of the summit guarantees a minimum of 25% meeting acceptance rates and at least four productive meetings with strong follow-up potential. Increase your meeting success rates and build meaningful collaborations in this exclusive setting.

"The opportunity had gone cold since the initial chats, with the other party generally hard to get hold of. Being able to use the partnering app ahead of the conference to not only find a time but have a table reserved for us to hash out a deal was super valuable and enabled us to close the partnership." Attendee ADC and Radiopharmaceuticals Pharma Partnering Summit


Speakers: Nick Traggis, Founder and Chief Executive Officer, Ambrosia Biosciences, Aimee Raleigh, Principal, Atlas Venture, Andrew Whittle, Global Head, Cardio-Renal-Metabolic BD AND L, Boehringer Ingelheim, Robrecht Thoonen, Senior Director, External Innovation, Diabetes, Obesity and Cardiometabolic Diseases, Eli Lilly and Company, Ashley Zehnder, Founder and Chief Executive Officer, Fauna Bio, Clare Bernard, Venture Partner, F-Prime, Anthony Philippakis, General Partner, GV, Jordan Shin, Chief Medical Officer, HAYA Therapeutics, Jens Eckstein, Investment Partner and Member of the Board of Advisors, Hevolution Foundation and Apollo Health Ventures, Rajiv Patni, Chief Executive Officer, Judo Bio, Chris Lu, Chief Executive Officer, Laekna Therapeutics, Kasper Veje, Vice President, Head of Diabetes and Obesity Search and Evaluation, Novo Nordisk, Sam Murphy, Chief Executive Officer, SalubrusBio, Marc Abrams, Chief Technology Officer and Head of US Operations, SanegeneBio, Philip Just Larsen, Chief Executive Officer, SixPeaks Bio, Alicia Irurzun-Lafitte, Partner, UCB Ventures, David Moller, Chief Scientific Officer, Variant Bio, Jason Ruth, Sector Lead, Biotech Private Investments, Wellington Management